Goldman Sachs Portfolio holdings
Goldman Sachs, founded in 1869 by Marcus Goldman and later joined by Samuel Sachs, is a premier global investment bank headquartered in New York City, renowned for its influential role in financial markets. The firm provides a wide range of services, including investment banking (mergers, acquisitions, and underwriting), securities trading, asset management, and consumer banking through its Marcus platform, catering to corporations, governments, institutions, and high-net-worth individuals. Known for its elite status on Wall Street, Goldman Sachs has a history of navigating major economic events, from the Great Depression to the 2008 financial crisis, where it played a controversial yet pivotal role. With a strong emphasis on innovation and a global footprint, it manages billions in assets and remains a powerhouse in shaping economic policy and market trends.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
State Street SPDR S&P 500 ETF Trust
SPY
|
+$4.27B |
| 2 |
Zimmer Biomet
ZBH
|
+$3.42B |
| 3 |
TransUnion
TRU
|
+$1.8B |
| 4 |
Qualcomm
QCOM
|
+$587M |
| 5 |
Alibaba
BABA
|
+$434M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Gilead Sciences
GILD
|
+$1.06B |
| 2 |
Pfizer
PFE
|
+$895M |
| 3 |
iShares Russell 2000 ETF
IWM
|
+$631M |
| 4 |
RTX Corp
RTX
|
+$546M |
| 5 |
State Street SPDR Dow Jones Industrial Average ETF Trust
DIA
|
+$516M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Financials | 8.41% |
| 2 | Healthcare | 8.04% |
| 3 | Technology | 7.66% |
| 4 | Energy | 6.94% |
| 5 | Consumer Discretionary | 6.37% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
6101
ProQR Therapeutics
PRQR
$244M
| $188K | ﹤0.01% |
11,273
-7,776
| -41% | -$146K |
|
|
PGTI
6102
DELISTED
PGT, Inc.
PGTI
| $188K | ﹤0.01% |
12,926
-32,204
| -71% | -$400K |
|
|
TGA
6103
DELISTED
Transglobe Energy Corp
TGA
| $188K | ﹤0.01% |
47,088
+27,242
| +137% | +$113K |
|
|
IMOS
6104
ChipMOS TECHNOLOGIES
IMOS
$1.59B
| $186K | ﹤0.01% |
7,723
+1,670
| +28% | +$42.9K |
|
|
DTV
6105
PUT
DELISTED
DIRECTV COM STK (DE)
DTV
| $186K | ﹤0.01% |
2,000
-505,900
| -100% | -$45.7M |
|
6106
Chefs' Warehouse
CHEF
$4.31B
| $185K | ﹤0.01% |
8,733
-4,030
| -32% | -$80.5K |
|
|
SVA
6107
DELISTED
Sinovac Biotech, Ltd
SVA
| $185K | ﹤0.01% |
35,202
-56,026
| -61% | -$296K |
|
|
ENZN
6108
DELISTED
ENZON PHARMACEUTICALS INC
ENZN
| $184K | ﹤0.01% |
153,222
-4,034
| -3% | -$5.14K |
|
|
RVLT
6109
DELISTED
Revolution Lighting Technologies, Inc. - Class A
RVLT
| $184K | ﹤0.01% |
15,868
+14,850
| +1,459% | +$179K |
|
|
VRNG
6110
DELISTED
VRINGO, INC COM STK NEW (DE)
VRNG
| $184K | ﹤0.01% |
33,112
+16,892
| +104% | +$110K |
|
6111
Citizens
CIA
$248M
| $183K | ﹤0.01% |
24,571
+7,426
| +43% | +$46.5K |
|
6112
CALL
Clarus
CLAR
$125M
| $183K | ﹤0.01% |
+19,888
| New | +$187K |
|
6113
Lipocine
LPCN
$17.1M
| $183K | ﹤0.01% |
1,253
-43
| -3% | -$5.34K |
|
6114
Sonoma Pharmaceuticals
SNOA
$5.26M
| $183K | ﹤0.01% |
+143
| New | +$134K |
|
6115
Triumph Financial Inc
TFIN
$1.81B
| $183K | ﹤0.01% |
13,922
-9,583
| -41% | -$126K |
|
|
SDPI
6116
DELISTED
Superior Drilling Products Inc.
SDPI
| $183K | ﹤0.01% |
66,465
-2
| -0% | -$7 |
|
|
NVIV
6117
DELISTED
InVivo Therapeutics Holdings Corp
NVIV
| $183K | ﹤0.01% |
+1
| New | +$264K |
|
6118
Valhi
VHI
$389M
| $182K | ﹤0.01% |
2,674
-704
| -21% | -$54.8K |
|
|
FSAM
6119
DELISTED
Fifth Street Asset Management Inc. Class A
FSAM
| $182K | ﹤0.01% |
17,695
-339
| -2% | -$3.56K |
|
6120
Akebia Therapeutics
AKBA
$338M
| $181K | ﹤0.01% |
+17,616
| New | +$150K |
|
6121
PUT
FTI Consulting
FCN
$5.14B
| $181K | ﹤0.01% |
4,400
+1,900
| +76% | +$75.7K |
|
6122
CALL
GATX Corp
GATX
$6.45B
| $181K | ﹤0.01% |
3,400
-4,400
| -56% | -$250K |
|
6123
NanoViricides
NNVC
$39.3M
| $181K | ﹤0.01% |
5,238
+4,631
| +763% | +$176K |
|
6124
CALL
Voya Financial
VOYA
$8.96B
| $181K | ﹤0.01% |
3,900
+2,100
| +117% | +$94.6K |
|
|
OMCC
6125
DELISTED
Old Market Capital Corp
OMCC
| $181K | ﹤0.01% |
+14,250
| New | +$189K |
|
Similar funds
Goldman Sachs's Q2 2015 Portfolio in Review
As of Q2 2015, Goldman Sachs held 7,731 positions worth $323B, up 3.7% from $311B the previous quarter. Its ten largest holdings account for 14% of the portfolio.
Goldman Sachs deployed $13.1B of net new capital in Q2 2015, opening 673 new positions and adding to 3,224 existing holdings. Its largest new stake was TransUnion: 72,355,340 shares worth $1.82B.
By sector, the portfolio is most concentrated in Financials at 8.4% of assets, up from 8% a quarter earlier, followed by Healthcare and Technology.
On the sell side, the largest reduction was Gilead Sciences, an estimated $1.06B trimmed.
- Goldman Sachs's largest Q2 2015 buy was TransUnion: 72,355,340 shares worth $1.82B.
- Goldman Sachs added most to State Street SPDR S&P 500 ETF Trust in Q2 2015, an estimated $4.27B increase.
- Goldman Sachs's biggest Q2 2015 reduction was Gilead Sciences, cutting an estimated $1.06B.
- Goldman Sachs fully exited LORILLARD INC COM STK in Q2 2015, selling an estimated $386M.
- Goldman Sachs's ten largest holdings make up 14% of its $323B portfolio in Q2 2015.
- Goldman Sachs opened 673 new positions and closed 497 in Q2 2015.
- Goldman Sachs's portfolio value rose 3.7% quarter-over-quarter to $323B.
Based on Goldman Sachs's 13F filing for Q2 2015, filed 14 Aug 2015.